Isoprenoid metabolism in apicomplexan parasites.
Isoprenoid metabolism in apicomplexan parasites.
复制标题
DOI：
10.1007/s40588-014-0006-7
复制
发表时间：
2014-12-01
影响因子：
5.2
通讯作者：
Odom, Audrey R
中科院分区：
文献类型：
--
作者：
Imlay, Leah;Odom, Audrey R
Apicomplexan寄生虫包括一些最流行和致命的人类病原体。迫切需要新的抗寄生虫药物。异戊二烯类化合物的合成和代谢可能为治疗干预提供多个靶点。顶体定位的甲基赤藓糖醇磷酸(MEP)合成异戊二烯前体的途径不同于哺乳动物宿主使用的甲氧戊酸(MVA)途径，这一途径显然在大多数顶复合体中是必不可少的。在本文中，我们讨论了异戊二烯在顶端复合体寄生虫中产生和代谢命运的研究现状，包括宿主异戊二烯前体和下游产物的获取。我们描述了最近在顶端复合体寄生虫中识别第一个MEP途径调节因子的工作，并介绍了正在进行的对这一经过充分验证的抗寄生虫靶标的研究的几个有前途的领域。
Apicomplexan parasites include some of the most prevalent and deadly human pathogens. Novel antiparasitic drugs are urgently needed. Synthesis and metabolism of isoprenoids may present multiple targets for therapeutic intervention. The apicoplast-localized methylerythritol phosphate (MEP) pathway for isoprenoid precursor biosynthesis is distinct from the mevalonate (MVA) pathway used by the mammalian host, and this pathway is apparently essential in most Apicomplexa. In this review, we discuss the current field of research on production and metabolic fates of isoprenoids in apicomplexan parasites, including the acquisition of host isoprenoid precursors and downstream products. We describe recent work identifying the first MEP pathway regulator in apicomplexan parasites, and introduce several promising areas for ongoing research into this well-validated antiparasitic target.